Cargando…

Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry

BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions....

Descripción completa

Detalles Bibliográficos
Autores principales: Hwong, Wen Yea, Abdul Aziz, Zariah, Sidek, Norsima Nazifah, Bots, Michiel L., Selvarajah, Sharmini, Kappelle, L. Jaap, Sivasampu, Sheamini, Vaartjes, Ilonca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701494/
https://www.ncbi.nlm.nih.gov/pubmed/29169331
http://dx.doi.org/10.1186/s12883-017-0984-1
_version_ 1783281354302029824
author Hwong, Wen Yea
Abdul Aziz, Zariah
Sidek, Norsima Nazifah
Bots, Michiel L.
Selvarajah, Sharmini
Kappelle, L. Jaap
Sivasampu, Sheamini
Vaartjes, Ilonca
author_facet Hwong, Wen Yea
Abdul Aziz, Zariah
Sidek, Norsima Nazifah
Bots, Michiel L.
Selvarajah, Sharmini
Kappelle, L. Jaap
Sivasampu, Sheamini
Vaartjes, Ilonca
author_sort Hwong, Wen Yea
collection PubMed
description BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions. METHODS: From Malaysian National Stroke Registry, we included patients with non-fatal ischemic stroke. Prescriptions of antiplatelet, anticoagulants, antihypertensive drugs and lipid-lowering drugs were assessed. Multi-level logistic regressions were performed to determine the relation between potential factors and drug prescriptions. RESULTS: Of 5292 patients, 48% received antihypertensive drugs, 88.9% antiplatelet and 88.7% lipid-lowering drugs upon discharge. Thirty-three percent of patients with an indication for anticoagulants (n = 391) received it. Compared to patients <=50 years, patients above 70 years were less likely to receive antiplatelet (OR: 0.72, 95% CI: 0.50–1.03), lipid-lowering drugs (OR: 0.66, 95% CI: 0.45–0.95) and anticoagulants (OR: 0.27, 95% CI: 0.09–0.83). Patients with moderate to severe disability upon discharge had less odds of receiving secondary preventive drugs; an odds ratio of 0.57 (95% CI: 0.45–0.71) for antiplatelet, 0.86 (95% CI: 0.75–0.98) for antihypertensive drugs and 0.78 (95% CI: 0.63–0.97) for lipid-lowering drugs in comparison to those with minor disability. Having prior specific comorbidities and drug prescriptions significantly increased the odds of receiving these drugs. No differences were found between sexes and ethnicities. CONCLUSIONS: Prescription of antihypertensive drugs and anticoagulants among ischemic stroke patients in Malaysia were suboptimal. Efforts to initiate regular clinical audits to evaluate the uptake and effectiveness of secondary preventive strategies are timely in low and middle-income settings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12883-017-0984-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5701494
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57014942017-12-04 Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry Hwong, Wen Yea Abdul Aziz, Zariah Sidek, Norsima Nazifah Bots, Michiel L. Selvarajah, Sharmini Kappelle, L. Jaap Sivasampu, Sheamini Vaartjes, Ilonca BMC Neurol Research Article BACKGROUND: Evaluation of secondary stroke prevention in low and middle-income countries remains limited. This study assessed the prescription of secondary preventive drugs among ischemic stroke patients upon hospital discharge in Malaysia and identified factors related to the prescribing decisions. METHODS: From Malaysian National Stroke Registry, we included patients with non-fatal ischemic stroke. Prescriptions of antiplatelet, anticoagulants, antihypertensive drugs and lipid-lowering drugs were assessed. Multi-level logistic regressions were performed to determine the relation between potential factors and drug prescriptions. RESULTS: Of 5292 patients, 48% received antihypertensive drugs, 88.9% antiplatelet and 88.7% lipid-lowering drugs upon discharge. Thirty-three percent of patients with an indication for anticoagulants (n = 391) received it. Compared to patients <=50 years, patients above 70 years were less likely to receive antiplatelet (OR: 0.72, 95% CI: 0.50–1.03), lipid-lowering drugs (OR: 0.66, 95% CI: 0.45–0.95) and anticoagulants (OR: 0.27, 95% CI: 0.09–0.83). Patients with moderate to severe disability upon discharge had less odds of receiving secondary preventive drugs; an odds ratio of 0.57 (95% CI: 0.45–0.71) for antiplatelet, 0.86 (95% CI: 0.75–0.98) for antihypertensive drugs and 0.78 (95% CI: 0.63–0.97) for lipid-lowering drugs in comparison to those with minor disability. Having prior specific comorbidities and drug prescriptions significantly increased the odds of receiving these drugs. No differences were found between sexes and ethnicities. CONCLUSIONS: Prescription of antihypertensive drugs and anticoagulants among ischemic stroke patients in Malaysia were suboptimal. Efforts to initiate regular clinical audits to evaluate the uptake and effectiveness of secondary preventive strategies are timely in low and middle-income settings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12883-017-0984-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-23 /pmc/articles/PMC5701494/ /pubmed/29169331 http://dx.doi.org/10.1186/s12883-017-0984-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hwong, Wen Yea
Abdul Aziz, Zariah
Sidek, Norsima Nazifah
Bots, Michiel L.
Selvarajah, Sharmini
Kappelle, L. Jaap
Sivasampu, Sheamini
Vaartjes, Ilonca
Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title_full Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title_fullStr Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title_full_unstemmed Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title_short Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry
title_sort prescription of secondary preventive drugs after ischemic stroke: results from the malaysian national stroke registry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701494/
https://www.ncbi.nlm.nih.gov/pubmed/29169331
http://dx.doi.org/10.1186/s12883-017-0984-1
work_keys_str_mv AT hwongwenyea prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT abdulazizzariah prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT sideknorsimanazifah prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT botsmichiell prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT selvarajahsharmini prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT kappelleljaap prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT sivasampusheamini prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry
AT vaartjesilonca prescriptionofsecondarypreventivedrugsafterischemicstrokeresultsfromthemalaysiannationalstrokeregistry